Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026 Plans to Present Final Results and Subset Analysis of WM Patients from the Phase 2 CLOVER WaM Clinical Study of Iopofosine I 131 Anticipates Dosing of First Patients in Phase 1b Study of CLR 125 for the Treatment of Triple Negative Breast Cancer in 1Q ...